ACC: Empagliflozin Cuts Heart Failure Hospitalization Risk After AMI
By Elana Gotkine HealthDay Reporter
MONDAY, April 8, 2024 -- For patients with acute myocardial infarction at risk for heart failure, empagliflozin reduces the risk for heart failure hospitalization, according to a study published online April 6 in Circulation to coincide with the annual meeting of the American College of Cardiology, held from April 6 to 8 in Atlanta.
Adrian Hernandez, M.D., from Duke University in Durham, North Carolina, and colleagues examined the impact of empagliflozin on first and recurrent heart failure events in patients after myocardial infarction in a double-blind, randomized trial. The study included 6,522 patients hospitalized for acute myocardial infarction at risk for heart failure based on newly developed left ventricular ejection fraction of <45 percent and/or signs or symptoms of congestion.
The researchers found that the risk for first heart failure hospitalization and total heart failure hospitalizations was significantly lower in the empagliflozin group versus the placebo group during a median follow-up of 17.9 months (hazard ratio, 0.77 for first heart failure hospitalization; rate ratio, 0.67 for total heart failure hospitalizations). For first and total heart failure hospitalizations, the benefit of empagliflozin was consistent across clinically relevant patient subgroups. Patients randomly assigned to empagliflozin had less postdischarge need for new use of diuretics, renin-angiotensin modulators, and mineralocorticoid receptor antagonists.
"These data suggest the potential role for empagliflozin in high-risk post-myocardial infarction patients in preventing heart failure hospitalizations," the authors write.
Several authors disclosed ties to biopharmaceutical companies, including Boehringer Ingelheim and Eli Lilly, which manufacture empagliflozin and funded the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted April 2024
Read this next
ADA: Semaglutide Similarly Effective in Men, Women With Obesity-Linked Heart Failure
WEDNESDAY, June 26, 2024 -- For patients with obesity-related heart failure with preserved ejection fraction (HFpEF), semaglutide reduces body weight to a greater extent in women...
Triglyceride-Glucose Index Independently Linked to All-Cause Mortality
FRIDAY, June 21, 2024 -- The triglyceride-glucose (TyG) index is independently associated with all-cause mortality among patients with heart failure and chronic kidney disease...
Diet-Induced Inflammation Positively Tied to Marker of Heart Failure
THURSDAY, June 6, 2024 -- There is a positive correlation between diet-induced inflammation and a heart failure biomarker, according to a study published online June 5...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.